Opens in a new tab or window SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with ...

Results of CHANCE 2005/CARES-005 study were unveiled by Dr Gao-Jun Teng from Zhongda Hospital, Southeast University, China, ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

TACE has been shown to improve survival compared with best supportive care in meta-analyses of randomized trials. HCC shows chemoresistance, thus the role of embolization might be more important ...

Adding a monoclonal antibody cocktail to standard therapy for inoperable liver cancer has nearly doubled disease-free survival time, according to The Lancet. Traditionally, transarterial ...

Methods: Consecutive HCC patients with BCLC stage A, treated by hepatectomy alone (HA) or hepatectomy with TACE (HT), were retrospectively enrolled. Propensity score matching (PSM) was used to balance ...

Like most of the TNF super family members, TNF-α is synthesized as a 26 kDa type II transmembrane protein (tmTNF), which is subsequently cleaved in the extracellular domain by the metalloprotease ...

Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, ...